Pharmacoresistance in epilepsy : A pilot PET study with the P-glycoprotein substrate R-[¹¹C]verapamilLANGER, Oliver; BAUER, Martin; ZIMPRICH, Friedrich et al.Epilepsia (Copenhagen). 2007, Vol 48, Num 9, pp 1774-1784, issn 0013-9580, 11 p.Article

Abscess penetration of cefpirome: concentrations and simulated pharmacokinetic profiles in pusSAUERMANN, Robert; FEURSTEIN, Thomas; ZEITLINGER, Markus et al.European journal of clinical pharmacology. 2012, Vol 68, Num 10, pp 1419-1423, issn 0031-6970, 5 p.Article

Age dependency of cerebral P-gp function measured with (R)-[¹¹C]verapamil and PETBAUER, Martin; KARCH, Rudolf; NEUMANN, Friederike et al.European journal of clinical pharmacology. 2009, Vol 65, Num 9, pp 941-946, issn 0031-6970, 6 p.Article

A Combined Accelerator Mass Spectrometry-Positron Emission Tomography Human Microdose Study with ¹⁴C- and ¹¹C-Labelled VerapamilWAGNER, Claudia C; SIMPSON, Marie; LAPPIN, Graham et al.Clinical pharmacokinetics. 2011, Vol 50, Num 2, pp 111-120, issn 0312-5963, 10 p.Article

Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrierBAUER, Martin; KARCH, Rudolf; NEUMANN, Friederike et al.Journal of cerebral blood flow and metabolism. 2010, Vol 30, Num 3, pp 510-515, issn 0271-678X, 6 p.Article